Glenmark Pharmaceuticals Limited

GLENMARK

INE935A01035

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 03:17:55 2024-05-18 am EDT			5-day change	1st Jan Change
1,042 ^INR	+2.25%		+0.90%	+22.07%

May. 17	Glenmark Pharmaceuticals Receives ANDA Approval for Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution, 0.2%\|0.5%	CI
May. 13	Glenmark Pharmaceuticals to Acquire 26% Stake in Renewable Energy Company	MT

Glenmark Pharmaceuticals Limited Provides Earnings Guidance for the Fiscal Year 2022

November 14, 2021 at 10:00 pm EST

Glenmark Pharmaceuticals Limited provided earnings guidance for the fiscal year 2022. For the year, the company expects revenue growth to be around 10% to 15%.

Latest news about Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Receives ANDA Approval for Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution, 0.2%\|0.5%	May. 17	CI
Glenmark Pharmaceuticals to Acquire 26% Stake in Renewable Energy Company	May. 13	MT
Glenmark Pharmaceuticals Limited Appoints Shweta Munjal as Chief Communications & CSR Officer	May. 02	CI
Glenmark Pharmaceuticals Gets US FDA's Final Approval for Generic Pain Relief Medicines	Apr. 29	MT
Glenmark Pharmaceuticals Limited Receives Anda Approval for Acetaminophen and Ibuprofen Tablets, 250 Mg/125 Mg	Apr. 28	CI
Glenmark Lifesciences' Net Profit Slides in Fiscal Q4	Apr. 25	MT
Glenmark Pharmaceuticals Limited Announces Board Changes	Mar. 31	CI
Nirma Limited completed the acquisition of 75% stake in Glenmark Life Sciences Limited from Glenmark Pharmaceuticals Limited.	Mar. 11	CI
Nomura Adjusts Glenmark Pharmaceuticals’ Price Target to INR909 From INR841, Keeps at Neutral	Feb. 20	MT
Transcript : Glenmark Pharmaceuticals Limited, Q3 2024 Earnings Call, Feb 16, 2024	Feb. 15
Indian shares set to open higher	Feb. 14	RE
India's Glenmark Pharma posts loss for Q3 as remediation cost weighs	Feb. 14	RE
Glenmark Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 14	CI
Glenmark Pharma, Pfizer Launch Atopic Dermatitis Oral Treatment in India	Jan. 31	MT
Indian shares set to open higher ahead of national budget	Jan. 31	RE
Glenmark Pharmaceuticals Limited Partners with Pfizer to Launch Abrocitinib in India	Jan. 31	CI
Alphamab Oncology Unit, 3D Medicines Grants Glenmark Unit License to Commercialize Sarcoma Injectable	Jan. 24	MT
India's Glenmark Life Sciences posts Q3 profit rise; strong orderbook ahead, says CEO	Jan. 23	RE
Glenmark Pharmaceuticals Limited Launches Biosimilar of the Popular Antidiabetic Drug, Liraglutide, for the First Time in India	Jan. 02	CI
Glenmark Pharmaceuticals Introduces Anti-Diabetic Drug Liraglutide in India	Jan. 03	MT
Transcript : Glenmark Pharmaceuticals Limited, Q2 2024 Earnings Call, Nov 15, 2023	Nov. 14
Glenmark Pharmaceuticals Swings to Loss in Fiscal Q2; Shares Slide 5%	Nov. 14	MT
India's Glenmark Pharma posts Q2 loss on exceptional legal costs	Nov. 10	RE
Glenmark Pharmaceuticals Gets US FDA's Final Approval for Generic Anti-Psychotic Drug	Nov. 07	MT
Glenmark Pharmaceuticals Limited Receives ANDA Approval for Fluphenazine Hydrochloride Tablets USP, 1 mg, 2.5 mg, 5 mg, and 10 mg	Nov. 06	CI

Chart Glenmark Pharmaceuticals Limited

Duration

Period

More charts

Glenmark Pharmaceuticals Limited is an India-based global pharmaceutical company. The Company is focused on building a global formulation business with branded, generics and over the counter (OTC) segments in the therapy areas of dermatology, respiratory and oncology. The Company also has a regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. Its product portfolio includes topical products, liquids, respiratory MDI/DPI, complex injectables and biologics, and oral solids. The Company has a bioequivalent version of Tiotropium Bromide dry powder inhaler (DPI) under the brand, Tiogiva in the United Kingdom and Tavulus in Spain, for the treatment of chronic obstructive pulmonary disease. Ryaltris, the Company's first branded specialty product globally, is a fixed dose combination nasal spray that combines an antihistamine (Olopatadine) with a steroid (Mometasone Furoate) for treatment of allergic rhinitis.

Sector

Pharmaceuticals

Calendar

2024-05-23 - Q4 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Glenmark Pharmaceuticals Limited

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1,042 INR

Average target price

962.8 INR

Spread / Average Target

-7.64%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
GLENMARK PHARMACEUTICALS LIMITED	+22.07%	3.53B
SUN PHARMACEUTICAL INDUSTRIES LTD.	+21.63%	44.12B
OTSUKA HOLDINGS CO., LTD.	+23.26%	22.71B
SANDOZ GROUP AG	+18.22%	15.15B
CIPLA LIMITED	+12.66%	13.61B
ZYDUS LIFESCIENCES LIMITED	+60.18%	13.34B
ONO PHARMACEUTICAL CO., LTD.	-8.64%	6.84B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+15.65%	5.63B

Generic Pharmaceuticals